Liquid Biopsy for Precision Oncology Summit

Memo

The 4th Liquid Biopsy for Precision Oncology Summit unites biopharma, clinical and diagnostic teams to drive clinical adoption and finally push through the barriers to radically improve patient outcomes. An end-to-end conversation tackling everything from pre-analytical steps to expediting your product’s commercial success, this is your must-attend meeting for advancing liquid biopsy candidates into a commercial and clinical reality. This meeting allows you to discover the latest technologies and applications, demonstrating how to harness the improved specificity and sensitivity to characterize liquid biopsy samples and predictive biomarkers, such as exosomes, CTCs, ctDNA and RNA to expedite your drug development timelines. https://lbx-summit.com/ February 10-12, 2020 Contact:This email address is being protected from spambots. You need JavaScript enabled to view it.+1 415 735 3289   Price:Drug Developers**: USD 0.0 Speakers: Hua Fang, Clinical Biomarker Lead, ImmunoOncology, Oncology Early Clinical Development, AbbVie, Emmanuelle di Tomaso, VP, Head Oncology Biomarkers, Bayer, Sarah Paul, Principal Scientific Researcher and Biomarker Lead, Genentech, Christina Bender, Exploratory Biomarker and Oncology Commercialization Lead, Bristol-Myers Squibb, Jean-Francois Martini, Senior Director, Translational Oncology and Lead, Global Product Development, Pfizer, Lauren Leiman, Executive Director, BloodPAC Time: 8:00 am - 5:00 pm